Literature DB >> 10894264

The application of a lentiviral vector for gene transfer in fetal human hepatocytes.

M H Zahler1, A Irani, H Malhi, A T Reutens, C Albanese, B Bouzahzah, D Joyce, S Gupta, R G Pestell.   

Abstract

BACKGROUND: The applications of traditional retroviral vectors are limited because proviral integrations into the host genome require DNA synthesis. Lentiviruses are considered to be advantageous because of their ability to infect non-dividing cells.
METHODS: To demonstrate the potential of lentiviral vectors, we used a human immunodeficiency virus (HIV)-1 virus encoding the green fluorescence protein (GFP) to infect fetal human hepatocytes. GFP-expressing cells were transplanted into the liver of Balb/C SCID mice via intrasplenic injection.
RESULTS: Primary fetal hepatocytes incorporated the GFP reporter with high (30-40%) efficiency. A cell line derived from human fetal liver (HFL) exhibited similar transduction efficiency to the lentiviral vector. To demonstrate the relationship between lentiviral gene transfer and cell proliferation, cells were subjected to gamma-irradiation, which attenuated the replication of primary fetal hepatocytes. However, lentiviral gene transfer was unaffected by this decrease in cell proliferation. GFP expression in transduced cells was preserved during multiple passages in cell culture. When GFP-expressing cells were transplanted into the liver of Balb/C SCID mice via intrasplenic injection, GFP expression was observed throughout the 3 week duration of the study.
CONCLUSION: These studies establish that human hepatocytes are amenable to lentiviral gene transfer with sustained transgene expression. Incorporation of lentiviral vectors will be helpful in testing strategies for hepatic gene therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894264     DOI: 10.1002/(SICI)1521-2254(200005/06)2:3<186::AID-JGM100>3.0.CO;2-6

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

1.  Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.

Authors:  Albert Grinshpun; Reba Condiotti; Simon N Waddington; Michael Peer; Eli Zeig; Sima Peretz; Alina Simerzin; Janice Chou; Chi-Jiunn Pann; Hilla Giladi; Eithan Galun
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

2.  CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Authors:  Xuanmao Jiao; Marco A Velasco-Velázquez; Min Wang; Zhiping Li; Hallgeir Rui; Amy R Peck; James E Korkola; Xuelian Chen; Shaohua Xu; James B DuHadaway; Sandra Guerrero-Rodriguez; Sankar Addya; Daniela Sicoli; Zhaomei Mu; Gang Zhang; Andres Stucky; Xi Zhang; Massimo Cristofanilli; Alessandro Fatatis; Joe W Gray; Jiang F Zhong; George C Prendergast; Richard G Pestell
Journal:  Cancer Res       Date:  2018-01-22       Impact factor: 12.701

3.  Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes.

Authors:  Eva Ramboer; Tamara Vanhaecke; Vera Rogiers; Mathieu Vinken
Journal:  Methods Mol Biol       Date:  2015

4.  Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy.

Authors:  B Ren; B A O'Brien; M A Swan; M E Koina; N Nassif; M Q Wei; A M Simpson
Journal:  Diabetologia       Date:  2007-06-28       Impact factor: 10.122

5.  Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.

Authors:  Xuanmao Jiao; Min Wang; Zhao Zhang; Zhiping Li; Dong Ni; Anthony W Ashton; Hsin-Yao Tang; David W Speicher; Richard G Pestell
Journal:  Breast Cancer Res       Date:  2021-01-23       Impact factor: 6.466

Review 6.  Strategies for immortalization of primary hepatocytes.

Authors:  Eva Ramboer; Bram De Craene; Joery De Kock; Tamara Vanhaecke; Geert Berx; Vera Rogiers; Mathieu Vinken
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.